09:25 AM EDT, 08/12/2024 (MT Newswires) -- ImmunityBio ( IBRX ) said Monday that Anktiva is now available for patients under both commercial and government insurance plans in the US.

The US Food and Drug Administration approved Anktiva, the company's immunotherapy to treat Bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer, in April.

Additionally, ImmunityBio ( IBRX ) has started the filing procedure for getting regulatory approval for Anktiva in the EU and UK, and expects to complete the initial European Medicines Agency filing in Q4, the biotechnology firm added.

The company also said it has received regulatory approval to initiate patient enrollment in the Bacillus Calmette-Guerin naive trial in India.

ImmunityBio ( IBRX ) intends to file an application in South Africa in Q3 to start the BCG naive trial, it said.

Price: 4.6300, Change: +0.09, Percent Change: +1.98